Sunitinib malate and Hepatic mass - a phase IV clinical study of FDA data


Hepatic mass is reported only by a few people who take Sunitinib Malate.

The phase IV clinical study analyzes which people take Sunitinib malate and have Hepatic mass. It is created by eHealthMe based on reports of 8,899 people who have side effects while taking Sunitinib malate from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 24, 2023

8,899 people reported to have side effects when taking Sunitinib malate.
Among them, 5 people (0.06%) have Hepatic mass.

What is Sunitinib malate?

Sunitinib malate has active ingredients of sunitinib malate. eHealthMe is studying from 8,904 Sunitinib malate users for its effectiveness, alternative drugs and more.

What is Hepatic mass?

Hepatic mass is found to be associated with 792 drugs and 355 conditions by eHealthMe.

Number of Sunitinib malate and Hepatic mass reports submitted per year:

Could Sunitinib malate cause Hepatic mass?

Time on Sunitinib malate when people have Hepatic mass *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 100 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Hepatic mass when taking Sunitinib malate *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Hepatic mass when taking Sunitinib malate *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Sunitinib malate *:

  1. Gleevec: 5 people, 100.00%
  2. Simvastatin: 4 people, 80.00%
  3. Maxolon: 4 people, 80.00%
  4. Amlodipine: 4 people, 80.00%

Common side effects people have besides Hepatic mass *:

  1. Weakness: 5 people, 100.00%
  2. Heart Attack: 5 people, 100.00%
  3. Acute Myocardial Infarction (acute heart attack): 5 people, 100.00%
  4. Anaemia (lack of blood): 5 people, 100.00%
  5. Atrioventricular Block First Degree (heart block first degree): 5 people, 100.00%
  6. Ventricular Extrasystoles (premature cardiac contraction): 5 people, 100.00%
  7. Gastrointestinal Stromal Tumor: 5 people, 100.00%
  8. Malaise (a feeling of general discomfort or uneasiness): 5 people, 100.00%
  9. Nausea (feeling of having an urge to vomit): 5 people, 100.00%
  10. Lip Dry: 4 people, 80.00%

Common conditions people have *:

  1. Gastrointestinal Stromal Tumor: 5 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Sunitinib malate and have Hepatic mass?

Check whether Hepatic mass is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Hepatic mass and when was it recovered:

Expand to all the drugs that have ingredients of sunitinib malate:

Alternative drugs to, pros and cons of Sunitinib malate:

Common Sunitinib malate side effects:

Browse all side effects of Sunitinib malate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Hepatic mass treatments and more:

COVID vaccines that are related to Hepatic mass:

Common drugs associated with Hepatic mass:

All the drugs that are associated with Hepatic mass:

All the conditions that are associated with Hepatic mass:

How the study uses the data?

The study uses data from the FDA. It is based on sunitinib malate (the active ingredients of Sunitinib malate) and Sunitinib malate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: